Changing Times Vitamins, Inc. (SGTB): A lot of people lost money.

Play Episode

12min

Proactive - Interviews for investors

hVIVO CEO on record FY24 revenue & EBITDA as expansion strategy pays off

hVIVO PLC chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s record-breaking financial performance in 2024, operational milestones and strategic outlook. hVIVO reported a 12% rise in revenue to just under £63 million, with an EBITDA margin of 26%. Khan highlighted this as a record margin for the company. He noted that, even excluding a one-off facility fee, the margin remained strong at 23%. The company also ended the year with £44 million in cash. Khan explained: “This is all been based on a record number of inoculations… we ran nine challenge trials and our largest field study to date.” He emphasised the company’s transformation, with a move to a purpose-built 50-bed human challenge facility in Canary Wharf, improvements in operational efficiency, and a major expansion of lab and outpatient capacity. Looking ahead, hVIVO is targeting £73 million in revenue for 2025, of which £70 million is already contracted. The company is also launching new challenge models, including Omicron and hMPV, and pursuing its first phase 3 human trial. Khan also discussed recent acquisitions—CRS in Germany and Cryostore in the UK—and confirmed continued dividend payments, with 0.2p per share set for June. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #hVIVO #ClinicalTrials #HumanChallengeTrials #BiotechNews #EBITDA #RevenueGrowth #Biopharma #DrugDevelopment #CRSAcquisition #CryoStore #VaccineTrials #AntiviralResearch #LifeSciences #PharmaPipeline

Proactive - Interviews for investors

Nextech3D.ai signs LOI to sell majority stake in Toggle3D.ai securing strategic non-dilutive capital

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a pivotal strategic development for the company. Nextech3D.ai has entered into a Letter of Intent to sell up to an 80% equity interest in its spin-out subsidiary, Toggle3D.ai, to TQG Technologies. The proposed transaction not only transitions Toggle3D.ai into its next phase of evolution under new majority ownership, but also provides Nextech3D.ai with a non-dilutive capital infusion of CAD $610,000, strengthening the company’s balance sheet and strategic flexibility without impacting existing shareholder equity. Gappelberg explained that the transaction will be structured in three tranche wuth TQG Technologies acquireing 11 million shares of Toggle3D.ai for CAD $610,000 in cash. Contingent on the closing of TQG’s capital raise, an additional 5 million shares will be purchased for CAD $276,000. The final stage will complete the 80% acquisition through a combination of share purchases and the vending-in of TQG’s strategic assets into Toggle3D.ai. As part of the agreement framework, a non-refundable deposit of CAD $177,000 will be paid by TQG upon the finalization of the deal’s structure by its management. Further milestone-based payments are scheduled to be completed by August 2025. Additionally, Nextech3D.ai stands to receive a performance-based bonus of CAD $710,000 if TQG successfully closes a financing round of at least USD $5 million by that time. The two companies plan to issue a joint public announcement upon the execution of the definitive agreement and will coordinate a co-branded PR campaign to spotlight Toggle3D.ai’s new strategic direction and business roadmap under TQG’s leadership. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #toggle3d TQGtechnologies

Proactive - Interviews for investors

Futura Medical CEO James Barder on Futura’s 2024 strong growth, maiden profit and 2025 plans

Futura Medical PLC CEO James Barder takes Proactive's Stephen Gunnion through the company’s 2024 financial performance, market expansion and product pipeline. Futura reported a strong year in 2024, with CEO Barder highlighting revenue of £14 million and a maiden profit of £1.3 million—or £3.3 million excluding non-cash items. Barder noted that Eroxon is now sold in over 15 countries and is expected to reach over 20 by the end of 2025. “2024 was a very good year for us,” he said. Barder emphasised the company’s commitment to supporting commercial partners and building momentum behind its flagship product, Eroxon. He explained that markets seeing the most success were those effectively targeting men under 60 with mild to moderate erectile dysfunction—Eroxon’s most responsive user group. The conversation also touched on upcoming products, including Eroxon Intense, a variant delivering a stronger sensory experience, and SD4000, a topical treatment for female sexual dysfunction. Barder noted that 87% of women in clinical trials for SD4000 wished to continue use post-study—an encouraging sign. Looking ahead, Barder said the company will continue expanding its presence, drive forward its pipeline, and focus on areas it can control, despite share price frustrations. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell icon for updates. #FuturaMedical #Eroxon #EroxonIntense #SD4000 #ErectileDysfunction #FemaleHealth #PharmaNews #OTCProducts #HealthcareInnovation #BiotechUpdate

Proactive - Interviews for investors

Genflow Biosciences adds AI power to gene therapy through Heureka Labs collaboration

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new strategic partnership with US-based Heureka Labs, a spinoff of Duke University, to enhance its gene therapy research using AI technology. Leire said: “Every biotech in gene therapy should have an AI component. If you don't have that, you miss a critical tool to unlock value for your shareholders.” He stressed the need for a multi-omics approach—genomic, transcriptomic, and proteomic—to better understand gene expression and drug response, which traditional analysis methods struggle to fully capture. The partnership with Heureka Labs, which integrates deep AI and biological expertise, will initially support Genflow’s lead candidate, GF-1002, a SIRT-6 gene therapy targeting MASH (metabolic dysfunction-associated steatohepatitis). AI will help the company analyse complex preclinical data, including insights from nearly 700 mice tested, to understand mechanisms of action and identify likely responders—crucial in discussions with regulators such as the FDA and EMA. Leire also emphasised that the collaboration is scalable across Genflow’s pipeline, helping unlock synergies between programmes in liver, muscle, and eye diseases. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #GeneTherapy #AIinBiotech #BiotechNews #MASH #SIRT6 #HeurekaLabs #DrugDevelopment #MultiOmics #BiotechPartnership #FDA #EMA #PreclinicalResearch

Followers	77
Posts	19332
Boards Moderated	2
Alias Born	04/16/2019

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SGTB Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free